BioCardia Inc BCDA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
-
BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
-
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
-
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
-
BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference
-
BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval
-
BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results
Trading Information
- Previous Close Price
- $0.90
- Day Range
- $0.90–0.98
- 52-Week Range
- $0.75–1.80
- Bid/Ask
- $0.92 / $0.93
- Shares Outstanding
- 15.14M
- Market Cap
- $13.95M
- Volume/Avg
- 71,480 / 237,987
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
- Website
- https://www.biocardia.com
Valuation
|
Metric
|
BCDA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.11 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
BCDA
Financial Strength
|
Metric
|
BCDA
|
|---|---|
Quick Ratio | 2.02 |
Current Ratio | 2.09 |
Interest Coverage | — |
Quick Ratio
BCDA
Profitability
|
Metric
|
BCDA
|
|---|---|
Return on Assets (Normalized) | −178.59% |
Return on Equity (Normalized) | −989.45% |
Return on Invested Capital (Normalized) | −549.69% |
Return on Assets
BCDA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&b%%F% | LOCK|%Jh> | $135B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|N<vM#XL | LOCK|^d$x$ | $101B | |||
| Moderna Inc
MRNA
| LOCK|LS%?$W! | LOCK|D$ | $91B | |||
| argenx SE ADR
ARGX
| LOCK|y%MyMRL | LOCK|q>n | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|x!%QPn | LOCK|hW | $41B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|k!$$gyq? | LOCK|%%<R> | $30B | |||
| Incyte Corp
INCY
| LOCK|>>%lMy$ | LOCK|Z< | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|>$@vTT | LOCK|Nl | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|lr$hYHS | LOCK|<!Y#> | $21B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<&<vQ>k | LOCK|By> | $15B |
United States